Koers Aurinia Pharmaceuticals Inc. Toronto S.E.
Aandelen
AUP
CA05156V1022
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 223 mln. 305 mln. 209 mln. | Omzet 2025 * | 288 mln. 393 mln. 269 mln. | Marktkapitalisatie | 710 mln. 971 mln. 664 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -6 mln. -8,2 mln. -5,61 mln. | Nettowinst (verlies) 2025 * | 58 mln. 79,27 mln. 54,25 mln. | EV/omzet 2024 * | 1,64 x |
Nettoliquiditeiten 2024 * | 344 mln. 470 mln. 322 mln. | Nettoliquiditeiten 2025 * | 390 mln. 534 mln. 365 mln. | EV/omzet 2025 * | 1,11 x |
K/w-verhouding 2024 * |
-89,3
x | K/w-verhouding 2025 * |
12,4
x | Werknemers | 300 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,55% |
Recentste transcriptie over Aurinia Pharmaceuticals Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 16-06-93 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29-04-19 |
Robert Foster
FOU | Founder | 65 | 16-06-93 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 16-06-93 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 26-06-19 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,71 mld. | |
+1,69% | 22,02 mld. | |
-17,37% | 20,9 mld. | |
-9,30% | 17,85 mld. | |
-41,01% | 16,21 mld. | |
-14,85% | 15,52 mld. | |
+3,21% | 13,86 mld. | |
+33,54% | 12,04 mld. |